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to review fewer fi elds than recommended before de-
claring a sputum smear negative, but viewing just 
four fi elds through the 20× objective will already cor-
respond to the 100 fi elds required by ZN. Examining 
one full length of a smear corresponds to 500 ZN 
fi elds, and gives the greatest chance for LED FM to 
fulfi l its promise of increased sensitivity. 
As with any technology, poor implementation of 
LED FM may lead to underperformance. Fortunately, 
each of these pitfalls—hasty and poor training, over-
reading of scanty smears with ZN, and the use of 
40× or even 100× objectives for screening—can be 
overcome by using better approaches for training and 
quality assurance. These may vary from setting to 
setting and with the experience of the microscopist. 
To date, we have not seen any published studies mea-
suring LED FM profi ciency after different lengths of 
training. Such studies are critical to ensure that scale-
up of LED FM achieves the goals of reducing labora-
tory workload and increasing case detection, without 
increasing false-positive diagnoses. 
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Change to patient-centred terminology 
in tuberculosis: an important step, but 
what about the treatment strategies?
We read with great interest the article of Zachariah et 
al. and welcome the refl ection and recommendation 
towards more patient-centred terminology in tuber-
culosis (TB) programmes. The article laudably men-
tions that the lack of a strong, patient-centred ap-
proach to TB services is probably the most important 
reason for poor treatment completion rates. But will 
a change in terminology and/or defi nitions suddenly 
enhance treatment outcomes? 
We are concerned that TB programmes continue 
to focus mainly on directly observed therapy (DOT) 
as their recommended method of supervision. DOT 
has not been shown to improve treatment outcomes 
compared to self-administered therapy (SAT).1 While 
there is increasing emphasis on approaches that al-
low DOT to become more patient-focused, it still 
views patients as passive subjects of their treatment 
programmes. In many settings with a high prevalence 
of human immunodefi ciency virus (HIV) infection 
and TB that are often challenged with inadequate 
human resources for health, DOT is neither feasible 
nor practised. Rather, weeks of TB medication are 
dispensed to patients with little health education or 
treatment support. In recognition of this reality, the 
endorsement of the SAT strategy is critical. 
After more than a decade of prescribing antiretro-
viral therapy (ART), the HIV world has learned much 
about patient empowerment and its ability to enhance 
treatment outcomes. Recent interesting strategies in-
clude the use of community ART groups (CAGs) in 
Mozambique,2 and adherence clubs in Cape Town,3 
where patients are not only educated and prepared, 
they are also considered co-responsible for the treat-
ment of their illness. 
HIV treatment programmes have learned that treat-
ment strategies need not only to be adapted to the re-
ality of patients’ daily lives, they should also be owned 
by them to achieve optimal outcomes.4 A recent clus-
ter randomised trial in Uganda found that home-
based ART delivery was equivalent to facility-based 
ART delivery in terms of survival and virological sup-
pression.5 In Eastern Africa, various community mod-
els involving people living with HIV support drug 
distribution and patient follow-up, leading to reduced 
loss to follow-up.6
While the World Health Organization recognises 
the need to establish mechanisms for delivering inte-
grated TB and HIV services to co-infected patients,7 
only South Africa has created a manual to guide inte-
gration.8 In most settings two separate services con-
tinue to exist, with different and sometimes confl ict-
ing treatment approaches. 
When will we dare to integrate TB and HIV ser-
vices, especially in settings with high co-infection, 
and create patient-centred strategies that encourage 
the participation of patients as responsible, educated 
partners in their own treatment? 
We urge the TB world to move beyond lip-service 
to a patient-centred approach. Words are important, 
but evidence-based strategies to accompany them ex-
ist and must be implemented. 
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Xpert® MTB/RIF diagnosed disseminated 
smear-negative MDR-TB in a sub-district 
hospital in India
We report here the fi rst case of disseminated multidrug-
resistant tuberculosis (MDR-TB) diagnosed using the 
Xpert® MTB/RIF assay in a sub-district hospital in 
India. A 17-year-old boy was initially diagnosed with 
left-sided pleural tuberculosis (TB) at a regional TB 
treatment facility. He was started on World Health 
Organization (WHO) Category I anti-tuberculosis 
treatment with isoniazid, rifampicin (RMP), pyrazin-
amide and ethambutol. He improved clinically, with 
resolution of the pleural effusion. He later reported 
that he had missed several doses during treatment. 
Towards the end of treatment, in September 2010, 
he developed severe generalised abdominal pain. He 
had an emergency exploratory laparotomy with appen-
dectomy for presumed appendicitis. Omental biopsy 
demonstrated granulomatous infl ammation with focal 
caseation, consistent with TB peritonitis. He was then 
switched to the WHO Category II regimen (strepto-
mycin added). However, the surgical wound didn’t 
heal, with continued daily purulent discharge. 
He presented in November 2011 with low-grade 
fever, fatigue, abdominal pain and ongoing purulent 
drainage from the abdominal wounds. There were 
three ulcerated wounds on the abdomen at the prior 
surgical site. Weight was 35 kg compared to 58 kg in 
March 2010. The fl uid from the wound was negative 
for acid-fast bacilli (AFB) by Ziehl-Neelsen micros-
copy. Chest radiograph demonstrated new bilateral 
upper and mid-lung infi ltrates. He was unable to pro-
duce sputum for TB testing. He was negative for the 
human immunodefi ciency virus. Fluid from the ab-
dominal wound was tested with Xpert MTB/RIF, a 
nucleic-acid amplifi cation test for rapid detection of 
Mycobacterium tuberculosis and RMP resistance. The 
test was positive for TB (M. tuberculosis detected very 
low) and RMP resistance, and a diagnosis of dissemi-
nated MDR-TB was made. A specimen from the ab-
dominal wound was sent to another laboratory facil-
ity for mycobacterial culture, which was negative. 
Based on WHO guidelines and the patient’s treat-
ment history, MDR-TB treatment was started with 
kanamycin, high-dose levofl oxacin, ethionamide, cy-
closerine, amoxicillin/clavulanate and linezolid. He 
improved rapidly, with weight gain, reduced fatigue 
and malaise, cessation of discharge, and ultimately 
complete closure of the abdominal wounds. 
Diagnosis of extra-pulmonary TB poses many 
challenges: clinical presentation can be misleading 
and the performance of microscopy is generally poor. 
Moreover, at the sub-district level, the second-line di-
agnostic tools (i.e., culture and DNA probe assays) 
are often unavailable and/or expensive. In this case, 
Xpert MTB/RIF of abdominal fl uid allowed a rapid, 
bedside diagnosis of disseminated, chronic, culture-
negative MDR-TB in a patient with multiple differ-
ential diagnoses in a resource-limited setting. Early 
treatment interruption likely contributed to the de-
velopment of drug resistance, poor clinical response 
and subsequent dissemination. It took 2 months to 
receive the culture result, whereas prompt diagnosis 
by Xpert MTB/RIF saved crucial time and resources 
by sparing unnecessary trials of antibiotic therapy 
and delay in initiation of appropriate treatment. 
Based on recent studies, Xpert MTB/RIF in spe-
cifi c settings may prove superior to culture in the diag-
nosis of different forms of TB in terms of sensitivity, 
cost-effectiveness, and operational feasibility.1–4
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